X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Strides Arcolab with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES SHASUN LTD vs TORRENT PHARMA - Comparison Results

STRIDES SHASUN LTD    Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES SHASUN LTD TORRENT PHARMA STRIDES SHASUN LTD/
TORRENT PHARMA
 
P/E (TTM) x 32.5 36.7 88.7% View Chart
P/BV x 0.9 5.7 15.2% View Chart
Dividend Yield % 1.1 1.0 119.5%  

Financials

 STRIDES SHASUN LTD   TORRENT PHARMA
EQUITY SHARE DATA
    STRIDES SHASUN LTD
Mar-17
TORRENT PHARMA
Mar-17
STRIDES SHASUN LTD/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs1,2751,768 72.1%   
Low Rs9181,186 77.4%   
Sales per share (Unadj.) Rs389.6346.1 112.6%  
Earnings per share (Unadj.) Rs28.055.2 50.7%  
Cash flow per share (Unadj.) Rs48.973.3 66.7%  
Dividends per share (Unadj.) Rs4.5014.00 32.1%  
Dividend yield (eoy) %0.40.9 43.3%  
Book value per share (Unadj.) Rs303.1257.1 117.9%  
Shares outstanding (eoy) m89.42169.22 52.8%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.84.3 66.0%   
Avg P/E ratio x39.226.8 146.5%  
P/CF ratio (eoy) x22.420.1 111.3%  
Price / Book Value ratio x3.65.7 63.0%  
Dividend payout %16.125.4 63.4%   
Avg Mkt Cap Rs m98,036249,887 39.2%   
No. of employees `0005.811.8 49.2%   
Total wages/salary Rs m5,8819,934 59.2%   
Avg. sales/employee Rs Th6,005.94,971.5 120.8%   
Avg. wages/employee Rs Th1,014.0843.2 120.3%   
Avg. net profit/employee Rs Th431.2792.4 54.4%   
INCOME DATA
Net Sales Rs m34,83458,569 59.5%  
Other income Rs m1,6862,233 75.5%   
Total revenues Rs m36,52060,802 60.1%   
Gross profit Rs m6,42813,773 46.7%  
Depreciation Rs m1,8723,069 61.0%   
Interest Rs m2,2692,056 110.4%   
Profit before tax Rs m3,97310,881 36.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m40-   
Extraordinary Inc (Exp) Rs m-1,0060-   
Tax Rs m4701,545 30.4%   
Profit after tax Rs m2,5019,336 26.8%  
Gross profit margin %18.523.5 78.5%  
Effective tax rate %11.814.2 83.3%   
Net profit margin %7.215.9 45.0%  
BALANCE SHEET DATA
Current assets Rs m38,16553,841 70.9%   
Current liabilities Rs m30,40231,612 96.2%   
Net working cap to sales %22.338.0 58.7%  
Current ratio x1.31.7 73.7%  
Inventory Days Days7797 79.6%  
Debtors Days Days10484 124.7%  
Net fixed assets Rs m37,63942,079 89.4%   
Share capital Rs m894846 105.7%   
"Free" reserves Rs m26,21042,655 61.4%   
Net worth Rs m27,10543,501 62.3%   
Long term debt Rs m16,37722,408 73.1%   
Total assets Rs m81,168101,250 80.2%  
Interest coverage x2.86.3 43.7%   
Debt to equity ratio x0.60.5 117.3%  
Sales to assets ratio x0.40.6 74.2%   
Return on assets %5.911.3 52.2%  
Return on equity %9.221.5 43.0%  
Return on capital %12.119.6 61.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m13,46520,066 67.1%   
Fx outflow Rs m4,0765,304 76.8%   
Net fx Rs m9,38914,762 63.6%   
CASH FLOW
From Operations Rs m2,88110,127 28.5%  
From Investments Rs m-7,051-7,869 89.6%  
From Financial Activity Rs m3,382-1,918 -176.3%  
Net Cashflow Rs m-788212 -372.4%  

Share Holding

Indian Promoters % 27.7 71.5 38.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 7.0 538.5%  
FIIs % 8.6 12.6 68.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 8.8 294.3%  
Shareholders   56,241 26,511 212.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES SHASUN LTD With:   GSK PHARMA  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  IPCA LABS  NATCO PHARMA  

Compare STRIDES SHASUN LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day up 260 Points; Pharma Stocks Top Gainers(Closing)

After opening the day in red, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 10.7%

Jun 1, 2018 | Updated on Jun 1, 2018

For the quarter ended March 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 10.7% YoY). Sales on the other hand came in at Rs 17 bn (up 20.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES SHASUN LTD SHARE PRICE


Jun 22, 2018 (Close)

TRACK STRIDES SHASUN LTD

  • Track your investment in STRIDES SHASUN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES SHASUN LTD

STRIDES SHASUN LTD 8-QTR ANALYSIS

COMPARE STRIDES SHASUN LTD WITH

MARKET STATS